Subcutaneous Immunotherapy in Patients with Fagales Pollen-Induced Oral Allergy Syndrome by 諛뺢꼍�씗 et al.
389www.eymj.org
Oral allergy syndrome (OAS), also known as pollen-food aller-
gy syndrome, is one of the most common food allergies in 
adults and affects up to 70% of patients with allergies to pol-
len.1-3 The most extensively studied model of OAS is the so-called 
birch-apple syndrome, in which eating apples causes itching 
and hives in the mouth.4,5 Birch-apple syndrome is explained 
by the high structural homology between the major birch al-
lergen Bet v 1 and the major apple allergen Mal d 1.4,6 Taking 
into account the homology between the major allergens from 
birch and apple, it is reasonable to hypothesize that immuno-
therapy with birch pollen extract would improve apple allergy.4 
Indeed, previous studies have shown that pollen-specific im-
munotherapy could reduce OAS in patients with pollen-in-
duced allergic rhinoconjunctivitis (ARC).4,7-11 Nevertheless, at 
present, there is no consensus on the effectiveness of immuno-
therapy for OAS. The purpose of this study was to determine the 
effect of subcutaneous immunotherapy (SCIT) with Fagales 
pollens on the symptoms of OAS and ARC by measuring im-
provement in weighted symptom scores after SCIT. This study 
got permission from Severance Hospital Institutional Review 
Board (IRB Number: 4-2013-0397).
We screened 127 patients over 15 years of age with OAS who 
visited the Allergy Asthma Center at Severance Hospital in 
Seoul, Korea from January 2005 to December 2016. OAS was 
diagnosed on the basis of a history of seasonal pollen allergy, 
results of a skin prick test (SPT) or measurement of serum IgE 
(sIgE) by ImmunoCAP® (ThermoScientific, Uppsala, Sweden), 
and a review of patient medical records. We considered SPT 
positive if the wheal size of an allergen was larger than 3 mm, 
compared to negative control, and ImmunoCAP sIgE positive 
if the concentration was higher than 0.35 kU/L. SCIT was ad-
ministered with aqueous extracts of birch and oak pollens (Hol-
lister-Stier, Spokane, WA, USA). Patients were injected with a 
mixture of oak and birch pollen extracts with mean mainte-
nance doses of 0.34 mL at a concentration of 1:200 weight/
Subcutaneous Immunotherapy in Patients 
with Fagales Pollen-Induced Oral Allergy Syndrome
Nasil Kong1, Sunyoung Kim1, Sang Chul Lee1,2, Kyung Hee Park1,2, Jae-Hyun Lee1,2, and Jung-Won Park1,2
1Department of Internal Medicine and 2Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea.
Oral allergy syndrome (OAS) is the most common food allergy-related condition in adults. This study aimed to investigate whether 
subcutaneous immunotherapy (SCIT) with Fagales pollen-containing extracts can improve the clinical symptoms of OAS in Korea. 
In total, 56 OAS patients were included: 19 subjects treated with SCIT, which included Fagales pollen extracts, and 37 not treated 
with immunotherapy (IT). We reviewed the patients’ medical records and administered a telephone questionnaire at one point to 
assess baseline OAS features and changes in the patients’ OAS and allergic rhinoconjunctivitis (ARC) symptoms after treatment. 
Only 12 patients who received SCIT and 15 patients that did not receive SCIT could report on changes in OAS symptoms after treat-
ment because the other patients practiced strict avoidance of their culprit fruits and vegetables, and they could not respond to the 
status of OAS. SCIT reduced the severity of OAS (p=0.005). Nine of the 12 patients (75%) that received SCIT reported a more than 50% 
reduction in OAS symptoms. In contrast, only three of the 15 patients (20%) that did not receive IT reported more than a 50% reduc-
tion in OAS symptoms. SCIT also reduced the severity of ARC symptoms (p<0.001). The results indicate that SCIT with Fagales pol-
len-containing extracts is associated with improved OAS symptoms in Korea.
Key Words:  Oral allergy syndrome, subcutaneous immunotherapy, Fagales pollen
Brief Communication
pISSN: 0513-5796 · eISSN: 1976-2437
Received: November 26, 2018   Revised: February 2, 2019
Accepted: February 22, 2019
Corresponding author: Jung-Won Park, MD, PhD, Department of Internal Medi-
cine and Institute of Allergy, Yonsei University College of Medicine, Severance 
Hospital, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.
Tel: 82-2-2228-1961, Fax: 82-2-2227-7932, E-mail: parkjw@yuhs.ac
•The authors have no potential conflicts of interest to disclose.
© Copyright: Yonsei University College of Medicine 2019
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (https://creativecommons.org/licenses/
by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
Yonsei Med J 2019 Apr;60(4):389-394
https://doi.org/10.3349/ymj.2019.60.4.389
390
SCIT on Fagles Pollen-Induced OAS
https://doi.org/10.3349/ymj.2019.60.4.389
volume for birch and oak at every 4 weeks. The duration of 
SCIT varied from 82 days to 1735 days, with an average of 792.4 
days. Of the 127 patients with OAS, 40 were treated with SCIT 
and the other 87 were not. Eight of the 87 patients who did not 
receive SCIT during the study period were excluded because 
of a previous history of SCIT. We included 56 patients who 
could be contacted by phone from December 2016 to Febru-
ary 2017 to answer a questionnaire about their culprit fruits or 
vegetables and the presence and improvement of OAS and 
ARC symptoms. Nineteen of those patients received SCIT for 
allergens including Fagales pollens, and the other 37 patients 
did not receive immunotherapy. This study was approved by 
Severance Hospital Institutional Review Board (IRB number: 
2013-0397). The patients’ dispositions are summarized in Fig. 1.
The clinical features of the 56 patients are shown in Table 1. 
One of the patients that received SCIT and three of the patients 
that did not receive SCIT had experienced anaphylaxis due to 
fruit at the time of diagnosis. The mean weighted OAS symp-
tom scores were not different between the patients that re-
ceived SCIT and those that did not take IT. Although the tests 
for allergen-specific IgE (sIgE) were performed according to 
the OAS or seasonal ARC symptoms of each patient, we prefer-
entially checked the results for sIgEs for birch, oak, and apple 
for the purposes of this study. 
40 patients 
SCIT
87 patients 
Non-SCIT
8 patients 
previous SCIT
79 patients 
No previous SCIT
37 patients 
reply to questionnaire
42 patients 
non-reply
21 patients 
non-reply
19 patients 
reply to questionnaire
127 OAS patients 
Jan 2015–Dec 2016
Fig. 1. Flow chart of inclusion and exclusion of participants. SCIT, subcu-
taneous immunotherapy; OAS, oral allergy syndrome.
Table 1. Baseline Characteristics of Patients with OAS
SCIT group (n=19) Non-SCIT group (n=37) p value
Age (yr) 31.9±13.3 (15–69) 37.6±13.0 (17–74) 0.130
Gender, male/female 8/11 (42.1/57.9) 20/17 (54.1/45.9) 0.573
SCIT
Tree (alder, birch, oak, white ash) 19 (100) -
Grass (Bermuda, rye, timothy) 6 (31.6) -
Weed (ragweed, mugwort) 5 (26.3) -
HDM 10 (52.6) -
Others (cat, dog, alternaria) 6 (31.6) -
sIgE (kU/L), median (range)
Birch 47.9 (11.2–101.0) 25.4 (0.5–101.0) 0.234
Oak 19.4 (7.1–66.0) 16.0 (0.4–101.0) 0.401
Apple 5.3 (1.6–27.1) 3.9 (1.3–6.0) 0.118
Duration of SCIT (days) 792.4±474.6 (82–1735) -
Symptoms of OAS
Itchy oral mucosa, lips, throat 17 (89.5) 28 (75.7) 0.219
Swelling of oral mucosa, throat 10 (26.3) 16 (24.3) 0.505
Systemic skin symptoms 7 (36.8) 3 (8.1) 0.008
Respiratory symptoms 1 (5.3) 3 (8.1) 0.696
Gastrointestinal symptoms 0 (0) 6 (16.2) 0.063
Collapse, Shock 1 (5.3) 2 (5.4) 0.982
Weighted OAS symptom score, mean±SD 2.9±1.4 2.2±1.8 0.166
Symptoms of ARC
Rhinorrhea 16 (84.2) 30 (81.1) >0.999
Nasal obstruction 10 (52.6) 24 (64.9) 0.375
Sneezing 8 (42.1) 26 (70.3) 0.050
Eye itching 16 (84.2) 29 (78.4) 0.732
Number of ARC symptoms, mean±SD 2.6±1.0 3.0±1.0 0.254
SCIT, subcutaneous immunotherapy; sIgE, specific IgE; OAS, oral allergy syndrome; ARC, allergic rhinoconjunctivitis.
Values are presented as mean±standard deviation (range) or n (%) unless otherwise specified.
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The culprit foods causing OAS symptoms included fruits, 
nuts, vegetables, and others (Table 2). All 19 patients (100%) that 
received SCIT and 32 of the 37 patients (86.5%) that did not 
receive IT had OAS symptoms due to apples. The most com-
mon cause of OAS was apples in both groups of patients. In ad-
dition, patients had OAS symptoms due to various other fruits 
of the Rosaceae family, including peaches, plums, cherries, al-
monds, pears, apricots, and strawberries. Other triggering foods 
were fruits of the Cucurbitaceae family (e.g., melon, watermel-
on), the Rutaceae family (e.g., orange, clementine, citron), the 
Anacardiaceae family (e.g., mango, pistachio), and others. Le-
gumes, such as peanuts or soybeans, and tree nuts, including 
chestnuts, walnuts, hazelnuts, pine nuts, and macadamia, also 
triggered OAS symptoms. Some patients also suffered from al-
lergies to carrots, celeries, Chinese cabbage, and sweet potato. 
Because of the unique dietary culture of Korea, ginseng, bell-
flower root, and burdock root were also included among the 
offending foods.
Individual clinical manifestations of OAS were assessed by a 
questionnaire, which we administered by phone. The ques-
tionnaire contained items related to 1) offending foods, includ-
ing fruits, known to trigger OAS symptoms, 2) local or systemic 
clinical manifestations of OAS, and 3) degrees of improvement 
in OAS and ARC symptoms following treatment. We divided 
degrees of improvement into five levels according to the degree 
of subjective reduction in symptoms: 76–100% reduction, 51–
75% reduction, 26–50% reduction, 0–25% reduction, and wors-
ening of symptoms.
The symptoms of OAS ranged from localized mucosal in-
volvement to more severe forms with systemic organ involve-
ment affecting the skin, lungs, and gastrointestinal tract. The 
questionnaire items on OAS severity consisted of eight symp-
toms with three weighted scales for each symptom, which was 
modified from the questionnaire suggested by Bergmann, et al.10 
(Supplementary Table 1, only online). Localized symptoms 
were assigned 1 point, systemic symptoms with other organ in-
volvement were assigned 2 points, and anaphylaxis was as-
signed 3 points. The calculated weighted OAS score was deter-
mined with the following equation:
Mean weighted symptom score=∑ 8i=1weighti×symptomi. 
To assess the severity of ARC, the questionnaire included 
three nasal symptoms (rhinorrhea, nasal obstruction, sneez-
ing) and one eye symptom (eye itching) with two grade scores 
(0=no, 1=yes) for each symptom. 
Chi-squared and Fisher’s exact test was used to compare de-
grees of improvement in OAS and ARC symptoms. Student’s t-
test was used to compare age, sIgE levels, and OAS and ARC 
symptom scores between the patients that received SCIT and 
those that did not receive SCIT. p values <0.05 were consid-
ered statistically significant. All statistical analyses were per-
formed with Statistical Package for Social Sciences (SPSS), 
Table 2. Offending Fruits, Nuts, Vegetables, and Other Foods for Oral 
Allergy Syndrome
SCIT group (n=19) Non-SCIT group (n=37)
Fruits
Rosaceae
  Apple 19 (100) 32 (86.5)
Peach 14 (73.7) 29 (78.4)
Plum 8 (42.1) 9 (24.3)
Cherry 6 (31.6) 8 (21.6)
Almond 4 (21.1) 6 (16.2)
Pear 2 (10.5) 0 (0)
Apricot 0 (0) 1 (2.7)
Strawberry 0 (0) 1 (2.7)
Cucurbitaceae
Melon
 Cantaloupe 1 (5.3) 4 (10.8)
Korean melon 0 (0) 6 (16.2)
Watermelon 1 (5.3) 4 (10.8)
Rutaceae
Orange 0 (0) 1 (2.7)
Clementine 0 (0) 1 (2.7)
Citron 1 (5.3) 0 (0)
Anacardiaceae
Mango 1 (5.3) 1 (2.7)
Pistachio 1 (5.3) 0 (0)
Other fruits
 Banana 0 (0) 1 (2.7)
Pineapple 2 (10.5) 0 (0)
Grapes 1 (5.3) 2 (5.4)
Persimmon 1 (5.3) 2 (5.4)
Tomato 0 (0) 2 (5.4)
Avocado 1 (5.3) 0 (0)
Blueberry 0 (0) 1 (2.7)
Mulberry 1 (5.3) 0 (0)
Jujube 1 (5.3) 2 (5.4)
Legume/tree nuts
Legumes
Peanut 9 (47.4) 3 (8.1)
Soybean 5 (26.3) 10 (27.0)
Tree nuts
Chestnut 0 (0) 10 (27.0)
Walnut 1 (5.3) 2 (5.4)
Hazelnut 1 (5.3) 0 (0)
Pine nut 1 (5.3) 0 (0)
Macadamia 0 (0) 1 (2.7)
Vegetables
Apiaceae
Carrot 3 (15.8) 4 (10.8)
Celery 0 (0) 2 (5.4)
Other vegetables
Chinese cabbage 1 (5.3) 0 (0)
Sweet potato 0 (0) 1 (2.7)
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version 24 (IBM Corp., Armonk, NY, USA).
The efficacy of SCIT including Fagales pollen in patients 
with OAS is presented in Table 3. Because 7 of the 19 patients 
that received SCIT and 24 of the 39 patients that did not receive 
SCIT continued to avoid culprit fruits and vegetables after 
treatment, only 12 and 15 patients in those groups, respectively, 
reported on improvement in OAS symptoms. Chi-squared 
analysis with Fisher’s exact test showed that the patients that 
received SCIT had improved OAS symptoms (p=0.005), com-
pared with those that did not receive SCIT. Nine of the 12 pa-
tients (75%) that received SCIT reported that their OAS symp-
toms decreased by more than 50% after SCIT. In contrast, only 
three of the 15 patients (20%) that did not receive SCIT reported 
that their OAS symptoms decreased by 50% or more at the time 
of questionnaire evaluation during the follow-up. There was 
no difference in the duration of SCIT according to the degree of 
OAS improvement. None of the 19 patients that received SCIT 
reported any significant adverse events or worsening of OAS or 
ARC symptoms. Among the 37 patients that did not receive IT, 
one patient reported deterioration of OAS symptoms, and three 
patients reported that their ARC symptoms worsened.
Of the 19 patients that received SCIT overall, one had a his-
tory of severe systemic reactions due to raw carrots, but that 
patient did not have seasonal ARC symptoms. Excluding that 
patient, the 18 patients that received SCIT reported that their 
ARC symptoms improved after SCIT (chi-squared test, p<0.001), 
and 14 of those patients (77.8%) reported a greater than 50% 
improvement in ARC symptoms after SCIT. Only four of the 37 
(10.8%) patients that did not receive IT reported that their ARC 
symptoms improved by more than 50% (Table 4). 
The role of allergen-specific immunotherapy is a contro-
versial issue for IgE-mediated food allergies.12 SCIT has been 
applied to treat IgE-mediated food allergy, but it is not recom-
mended because of limited efficacy and a high risk of anaphy-
laxis.13 Recently, oral immunotherapy for allergies to eggs, milk, 
and peanuts have shown good efficacy,14-16 and European 
guidelines recommend oral immunotherapy for food allergies 
only for research centers with extensive experience.17
A few previous studies on the efficacy of SCIT for OAS treat-
ment have reported positive results; however,4,7-9,11,18 those 
studies used different dosages or compositions of birch pollen 
extracts, which might affect the efficacy of SCIT for OAS. Gen-
erally, the efficacy of SCIT for birch-apple syndrome is a con-
troversial issue,10,19,20 and Mauro, et al.4 emphasized the impor-
tance of a tailored dosage for each patient to achieve satisfactory 
efficacy. We used the recommended or maximum tolerable 
dosages to determine the maintenance doses of SCIT in our 
study; however, the recommended range for the maintenance 
dose of Bet v 1 for birch extract was quite wide (3.28–15 μg).21 
The maintenance dosage and route of administration of im-
munotherapy may be critical factors for the efficacy of SCIT in 
OAS.20,22 Our results show that SCIT with Fagales pollen-con-
taining extracts alleviated the symptoms of OAS and ARC. About 
75% of the patients that received SCIT reported that their OAS 
improved by more than 50%, which was significantly higher 
than the proportion of patients that did not receive immuno-
therapy who reported better than 50% improvement in their 
OAS symptoms. We identified one patient that had severe re-
actions including anaphylaxis to fresh fruits (apple, peach) and 
vegetables (carrot) without any ARC symptoms. That patient 
was sensitized with tree pollen and received immunotherapy 
for improvement of OAS symptoms only, not ARC symptoms. 
After receiving SCIT with birch and oak pollen extracts, the 
patient reported a 51–75% reduction in weighted OAS symp-
toms score. That level of efficacy was consistent with our ex-
pectations, considering the expected improvement of allergic 
rhinitis by SCIT. Randomized controlled studies have shown 
that SCIT reduced the symptoms of allergic rhinitis by 30–35% 
compared with placebo.23,24 Our data on the effects of SCIT on 
ARC symptoms were also comparable to previous results.23-25
Safety is another important concern in the use of SCIT to man-
age food allergies.13 In our study, none of the 19 patients that re-
ceived SCIT had significant adverse reactions. This result sup-
ports the safety and clinical feasibility of using SCIT to manage 
OAS. 
The results of previous surveys of Korean patients with OAS 
with pollen sensitization are not significantly different from 
those of Western surveys. The frequency of OAS was higher in 
patients sensitized to tree pollens and lower in patients sensi-
tized to grass pollens.26,27 Among the tree pollens, birch pollen 
is the most studied in terms of its relationship with OAS.4,11,22 
In Korea, birch pollen counts in the atmosphere are not high 
in the spring, during which oak pollen is the major tree pol-
Table 2. Offending Fruits, Nuts, Vegetables, and Other Foods (Continued)
SCIT group (n=19) Non-SCIT group (n=37)
Others
Ginseng 1 (5.3) 7 (18.9)
Bellflower root 0 (0) 2 (5.4)
Burdock root 0 (0) 1 (2.7)
SCIT, subcutaneous immunotherapy.
Data are presented as n (%).
Table 3. Improvement of Oral Allergy Syndrome Symptoms 
76–100% 51–75% 26–50% 0–25% Worsened
SCIT (n=12) 3 6 3 0 0
Non-SCIT (n=15) 1 2 1 10 1
SCIT, subcutaneous immunotherapy.
Chi-squared with Fisher’s exact test was done, and the p value was 0.005.
Table 4. Improvement of Allergic Rhinoconjunctivitis Symptoms
76–100% 51–75% 26–50% 0–25% Worsened
SCIT (n=18) 1 13 3 1 0
Non-SCIT (n=37) 1 3 5 24 4
SCIT, subcutaneous immunotherapy.
Chi-squared with Fisher’s exact test was done, and the p value was <0.001.
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len.28,29 Oak and birch both belong to the Fagales family. This 
suggests that cross-allergenicity between the two pollens may 
be important in Korea. We already reported on significant cross-
allergenicity between birch pollen and oak pollen using the 
sera of Korean patients with spring pollinosis, and cross-reac-
tivity between group 1 major allergens of birch and oak pollens 
has been reported.30,31 The presence of unique allergens for 
birch pollens or oak pollens cannot be excluded, however, so we 
applied immunotherapy with a mixture of oak and birch pol-
len extracts.
Because of the diversity among different geographical set-
tings and food cultures, different countries may have different 
culprit food allergens. We included patients with OAS caused 
by unique food materials, such as ginseng, bellflower root, and 
burdock root, in our study. Our results support the hypothesis 
that clinical features of OAS vary depending on the cultural dif-
ferences in favorable food materials. 
This study had several limitations because of its retrospective 
nature. We included only subjects who we could contact via 
phone calls to administer the symptom questionnaire; there-
fore, the participants did not necessarily represent the entire 
patient population. We do not know if characteristics, such as 
gender or age, might influence responses to the telephone ques-
tionnaire. Furthermore, the duration of immunotherapy varied 
from patient to patient. Some patients had completed SCIT 
(more than 3 years), while others were in the course of SCIT. 
The interval between the completion of treatment and admin-
istration of the questionnaire also varied from patient to pa-
tient, thus there might be bias due to the length of the patients’ 
memories. We measured efficacy on the basis of the patients’ 
subjective judgment rather than a more objective measure-
ment by double blind placebo controlled oral food challenge 
test. The small number of enrolled patients that received SCIT 
did not provide much statistical power. A multicenter study 
would be required to enroll a more satisfactory number of pa-
tients. Finally, as this study is a cross-sectional study, we just 
showed the association of OAS improvement and SCIT, and 
could not prove the efficacy of SCIT on OAS. Despite these lim-
itations, we think that more prospective randomized studies 
will prove that SCIT is beneficial for many patients with OAS.    
Our results show that SCIT with Fagales pollens extract is 
associated with greater improvement in OAS symptoms and 
safe treatment for OAS. As OAS is the most common subtype of 
food allergy in adults, we believe that SCIT can play a substan-
tial role in the treatment of adult food allergies.
ACKNOWLEDGEMENTS
This research was supported by a grant from the Korea Health 
Technology R&D Project through the Korea Health Industry De-
velopment Institute (KHIDI), funded by the Ministry of Health & 
Welfare, Republic of Korea (grant number: HI14C1324).
AUTHOR CONTRIBUTIONS
Conceptualization: PJW, KN. Data curation: KN, KS. Formal analysis: 
KN, PJW. Funding acquisition: PJW, PKH, LJH. Investigation: NK, KS, 
LSC. Methodology: KN, PJW. Project administration: NK, LSC, PKH. 
Resources: PJW, LJH. Software: KN. Supervision: PJW. Validation: PJW 
LJH, PKH. Visualization: KN, PJW. Writing—original draft: KN, PJW. 
Writing—review & editing: KN, PKH, PJW.
ORCID iDs
Nasil Kong https://orcid.org/0000-0001-7996-6550
Sunyoung Kim https://orcid.org/0000-0001-8159-2922
Sang Chul Lee https://orcid.org/0000-0001-5318-6804
Kyung Hee Park https://orcid.org/0000-0003-3605-5364
Jae-Hyun Lee https://orcid.org/0000-0002-0760-0071
Jung-Won Park https://orcid.org/0000-0003-0249-8749 
REFERENCES
1. Crespo JF, Rodriguez J. Food allergy in adulthood. Allergy 2003;58: 
98-113.
2. Fernández-Rivas M, Benito C, González-Mancebo E, de Durana DA. 
Allergies to fruits and vegetables. Pediatr Allergy Immunol 2008; 
19:675-81.
3. Lee SH, Ban GY, Jeong K, Shin YS, Park HS, Lee S, et al. A retro-
spective study of Korean adults with food allergy: differences in 
phenotypes and causes. Allergy Asthma Immunol Res 2017;9:534-9.
4. Mauro M, Russello M, Incorvaia C, Gazzola G, Frati F, Moingeon P, 
et al. Birch-apple syndrome treated with birch pollen immuno-
therapy. Int Arch Allergy Immunol 2011;156:416-22.
5. Eriksson NE, Wihl JA, Arrendal H. Birch pollen-related food hy-
persensitivity: influence of total and specific IgE levels. A multi-
center study. Allergy 1983;38:353-7.
6. Rodriguez J, Crespo JF, Lopez-Rubio A, De La Cruz-Bertolo J, Fer-
rando-Vivas P, Vives R, et al. Clinical cross-reactivity among foods of 
the Rosaceae family. J Allergy Clin Immunol 2000;106(1 Pt 1):183-9.
7. Möller C. Effect of pollen immunotherapy on food hypersensitivity 
in children with birch pollinosis. Ann Allergy 1989;62:343-5.
8. Herrmann D, Henzgen M, Frank E, Rudeschko O, Jäger L. Effect 
of hyposensitization for tree pollinosis on associated apple aller-
gy. J Investig Allergol Clin Immunol 1995;5:259-67.
9. Asero R. Effects of birch pollen-specific immunotherapy on apple 
allergy in birch pollen-hypersensitive patients. Clin Exp Allergy 
1998;28:1368-73.
10. Bergmann KC, Wolf H, Schnitker J. Effect of pollen-specific sublin-
gual immunotherapy on oral allergy syndrome: an observational 
study. World Allergy Organ J 2008;1:79-84. 
11. Bucher X, Pichler WJ, Dahinden CA, Helbling A. Effect of tree pol-
len specific, subcutaneous immunotherapy on the oral allergy syn-
drome to apple and hazelnut. Allergy 2004;59:1272-6.
12. Ebisawa M, Ito K, Fujisawa T; Committee for Japanese Pediatric 
Guideline for Food Allergy, The Japanese Society of Pediatric Aller-
gy and Clinical Immunology, The Japanese Society of Allergology. 
Japanese guidelines for food allergy 2017. Allergol Int 2017;66:248-
64.
13. Oppenheimer JJ, Nelson HS, Bock SA, Christensen F, Leung DY. 
Treatment of peanut allergy with rush immunotherapy. J Allergy 
Clin Immunol 1992;90:256-62.
14. Nurmatov U, Dhami S, Arasi S, Pajno GB, Fernandez-Rivas M, Mu-
raro A, et al. Allergen immunotherapy for IgE-mediated food allergy: 
394
SCIT on Fagles Pollen-Induced OAS
https://doi.org/10.3349/ymj.2019.60.4.389
a systematic review and meta-analysis. Allergy 2017;72:1133-47. 
15. Burks AW, Sampson HA, Plaut M, Lack G, Akdis CA. Treatment 
for food allergy. J Allergy Clin Immunol 2018;141:1-9.
16. Feuille E, Nowak-Wegrzyn A. Allergen-specific immunotherapies 
for food allergy. Allergy Asthma Immunol Res 2018;10:189-206.
17. Pajno GB, Fernandez-Rivas M, Arasi S, Roberts G, Akdis CA, Alva-
ro-Lozano M, et al. EAACI Guidelines on allergen immunothera-
py: IgE-mediated food allergy. Allergy 2018;73:799-815.
18. Okamoto Y, Kurihara K. [A case of oral allergy syndrome whose 
symptoms were dramatically improved after rush subcutaneous 
injection immunotherapy with pollen extracts of birch]. Arerugi 
2012;61:652-8.
19. Kinaciyan T, Jahn-Schmid B, Radakovics A, Zwölfer B, Schreiber C, 
Francis JN, et al. Successful sublingual immunotherapy with birch 
pollen has limited effects on concomitant food allergy to apple 
and the immune response to the Bet v 1 homolog Mal d 1. J Allergy 
Clin Immunol 2007;119:937-43. 
20. Hansen KS, Khinchi MS, Skov PS, Bindslev-Jensen C, Poulsen LK, 
Malling HJ. Food allergy to apple and specific immunotherapy 
with birch pollen. Mol Nutr Food Res 2004;48:441-8.
21. Nelson HS. Injection immunotherapy for inhalant allergens. In: 
Adkins NF, Bochner BS, Burks W, Busse WW, Holgate ST, Reman-
ske RF, et al, editors. Middleton’s allergy priciple and practice. Phil-
adelphia (PA): Elsevier Saunder; 2014. p.1416-37. 
22. Asero R. Effects of birch pollen SIT on apple allergy: a matter of 
dosage? Allergy 2004;59:1269-71.
23. Frew AJ, Powell RJ, Corrigan CJ, Durham SR; UK Immunotherapy 
Study Group. Efficacy and safety of specific immunotherapy with 
SQ allergen extract in treatment-resistant seasonal allergic rhino-
conjunctivitis. J Allergy Clin Immunol 2006;117:319-25.
24. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham 
S. Allergen injection immunotherapy for seasonal allergic rhinitis. 
Cochrane Database Syst Rev 2007;CD001936.
25. Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zahman H, et al. 
Allergen immunotherapy for allergic rhinoconjunctivitis: a sys-
temtatic review and meta-analysis. Allergy 2017;72:1597-631. 
26. Cho YS, Lim YJ, Lee JC, Kim SH, Lim MK, Yoo B, et al. Oral allergy 
syndrome in pollen-sensitized patients. J Asthma Allergy Clin Im-
munol 1998;18:458-65.
27. Park KH, Son YW, Lee SC, Jeong K, Sim da W, Park HJ, et al. Clini-
cal significance of component allergens in Fagales pollen-sensi-
tized peanut allergy in Korea. Allergy Asthma Immunol Res 2016; 
8:505-11.
28. Park HS, Chung DH, Joo YJ. Survey of airborne pollens in Seoul, 
Korea. J Korean Med Sci 1994;9:42-6.
29. Oh JW, Lee HB, Kang IJ, Kim SW, Park KS, Kook MH, et al. The re-
vised edition of Korean calendar for allergenic pollens. Allergy 
Asthma Immunol Res 2012;4:5-11. 
30. Jeong KY, Son M, Park JH, Park KH, Park HJ, Lee JH, et al. Cross-
reactivity between oak and birch pollens in Korean tree pollino-
sis. J Korean Med Sci 2016;31:1202-7.
31. Hauser M, Asam C, Himly M, Palazzo P, Voltolini S, Montanari C, 
et al. Bet v 1-like pollen allergens of multiple Fagales species can 
sensitize atopic individuals. Clin Exp Allergy 2011;41:1804-14. 
